FDA's Improved Forensics Uncovers More Manufacturing Data Integrity Issues
Agency learned how to find hidden information during its investigation of Ranbaxy, with techniques including improved forensic examinations of firm computers; mock inspections held at Indian and Chinese sites ahead of FDA visits.
You may also be interested in...
Gene therapy should remain on the market, FDA says, but Novartis could face civil or criminal penalties. Firm knew of problems before approval.
The generic drug maker’s Ranbaxy USA Inc. subsidiary pleads guilty to seven felony counts brought in connection with a longstanding government investigation into data integrity issues and manufacturing violations at two Indian sites, but while the settlement eliminates some worries for the firm, operations still face the weight of a FDA consent decree.
The apparently first-ever FDA press release for an advertising warning letter underscores importance of opioid issues – and the agency’s changing approach to media relations in general. FDA objects to Alkermes journal ad that excludes risk information about its opioid dependence treatment drug.